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or locorregional treatment. All patients were treated with direct IMRT. Toxicity was analyzed using the scale of Harris and van
Limbergen and Common Terminology Criteria for Adverse Events (CTCAE) Versión 4.0.
Results. We have evaluated 301 patients with a mean age of 52 years and a median following time of 15 months (3–39). 97% of
the patients received a boost over the tumor bed (91.3% with brachytherapy). 77.4% were inﬁltrating tumors; 22.6% were DCIS.
When ﬁnishing the treatment, 75.8% of the patients suffered grade 1 radiodermatitis (fully recovered after a month in 94.1%)
and hyperpigmentation was grade 1 in 48.2% patients thirty days after treatment. Chronically, ﬁbrosis appeared in 50% of the
patients (48.2%: grade 1 and 1.8%: grade 2) and hyperpigmentation remained grade 1 in 30.9% of patients. No grade 3 or 4 toxicity
was reported. We found that ﬁnal aesthetic result in the evolution critically depends on the state of the breast after surgery and
before radiotherapy.
Conclusion. Hypofractionated treatment in breast cancer is safe in terms of toxicity (acute and chronic) and very well tolerated
with good cosmetic outcomes. It also provides patients the opportunity to reduce their visits to the hospital and return to their
daily lives. Another important issue is the cost savings when compared to conventional treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.094
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Objective. To evaluate the inﬂuence of radiation dermatitis in the quality of life ofwomenwith breast cancer treatedwith radiation
therapy after conservative surgery.
Material and methods. Observational, prospective longitudinal done at the Department of Radiation Oncology-CHGUV-ERESA
between December and June 2012 in 35 patients requiring breast irradiation. Inclusion criteria: Conservative surgery, absence of
cognitive impairment and Spanish-speaking. The assessment of quality of lifewas performed using two validated questionnaires
for Spanish, DLQI1 and Skindex-292-3. Three surveys were conducted DLQI (the ﬁrst and last week of treatment and one month
after the end). The Skindex-29 was performed at the end of treatment and at three scales are rated: functional, emotional and
symptomatic. All patients followed the protocol radiodermatitis prevention of service.
Results. In the valuation of impaired quality of life on the end of treatment shows that in DLQI: only 3 participants had scores of
10 or higher on a total score of 30, this represents a low inﬂuence. When spend a month of the end of treatment, further reduces
this inﬂuence. The items on pain, burning and itching were the highest. In Skindex-29 only two women had scores of 35 and 38
out of 100 representing a half affectation. In the remaining women, affectation was low or very low.
Conclusions. Contrary to what is concluded in recent publications,1–5 this study shows a low alteration of the quality of life of
womenwith breast irradiation. These results are highly dependent on Radiation Oncology servicewhere treatment takes place as
they depend protocols on the acceptance of treatment and the protocols for prevention and management of radiation dermatitis
that are used in each service.
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Introduction. Breast radiodermatitis not always appear uniformly distributed throughout the breast. Throughout the treatment,
it is common to see more afectation in some areas than in others.
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Objective. Get a working method to help us improve nursing care in breast carcinoma radiodermatitis.Methods. An observational,
longitudinal and prospective study in 2012 on 35 women diagnosed with breast cancer radiotherapy after conservative surgery. To
evaluate the degree of radiationdermatitiswasused scale RTOG/EORTC. To locatewhere the ﬁrst signs orwhere further intensiﬁes
the degree of radiation dermatitis, was performed in addition to the general evaluation of the breast, an assessment by area.
Have differentiated localized in 9 areas: axilla, submammary fold, nipple, areola, supraclavicular and each of the quadrants of
the breast. The assessment of the signs of breast radiodermatitis was conducted in weekly from the ﬁrst to the last and one
month after stopping treatment.Results. During theweekly review, in 24 of the 35women appeared radiodermatitis degrees higher
when this assessment was carried out in speciﬁc areas when performed in the general assessment of the breast. Performing
radiodermatitis averages with RTOG scale, the overall breast showed a mean of 1, compared to 1.25 presented than the fold
and armpit and 1.11 was obtained in the nipple and areola.Conclusions. This evaluation of the breast radiodermatitis focused
differentiation gives us a much better risk areas as care to apply. Furthermore, we can observe the evolution and determine
speciﬁc areas of care against the valuation of the breast as a whole.
http://dx.doi.org/10.1016/j.rpor.2013.03.096
Importance of care in radiation therapy in breast
J. Buedo García1, A. González Sanchís1, R. In˜igo Valdenebro1, R. Martínez San Juan1, J. Gordo Partearroyo1,
L. Brualla González2, J. López Torrecilla1
1 Hospital General Universitario, Radioterapia, Spain
2 Hospital General Universitario, Radiofísica, Spain
Objective. To assess the effect of close monitoring and specialized care on the factors that inﬂuence the development of radio-
dermatitis in patients with breast irradiation.
Material and methods. Between December 2011 and June 2012 was an observational, longitudinal and prospective study in 35
patients with indications for breast irradiation. Weekly are evaluated the signs and symptoms of radiation dermatitis during
and for one month after stopping treatment by nursing unit in radiotherapy. To evaluate the inﬂuence of the following factors:
(1) Type of treatment and fractionation. (2) Age of the patient. (3) Areas of friction and high humidity areas. (4) Breast size. (5)
Nutritional status. (6) Skin phototype. (7) Application of metal-based cosmetics. To determine the degree of radiation dermatitis
have used the scale of the RTOG/EORTC.
Results. Of the 35 participants, 24 had in areas of friction or rubbing an increased degree of radiation dermatitis. Of all the factors
analyzed no differences by different dose fractionation, or age, breast size, nutritional status, skin type or increased by applying
zinc oxide in the treatment areas.
Conclusions. Of all the factors analyzed only be attributed to increased toxicity areas with excess moisture or friction such as the
underarm, the fold, the nipple and areola.
http://dx.doi.org/10.1016/j.rpor.2013.03.097
IMRT in breast cancer: Experience of CROASA group
A. Serradilla1, E. López2, F. Góngora3, G. Arregui4, J. Velasco3, D. Álvarez3, A. Barbosa3, J. Begara1, P. Moreno1,
R. Jiménez1, J. Gómez1, A. Domínguez1, A. Sacchetti 1
1 Clínica CROASA, Málaga, Oncología Radioterápica, Spain
2 Clinica ONCOSUR, Granada, Oncología Radioterápica, Spain
3 Clínica CROASA, Málaga, Radiofísica, Spain
4 Clínica ONCOSUR, Granada, Radiofísica, Spain
Introduction. Treatment to thewhole breastwith standard tangencial ﬁelds produces rather inhomogeneousdosedistributionsdue
to the variations in thickness across the target volume. The underlying ribs, lung and heart are in part included within the same
isodose as the target volume and hot spots are often found in areas of reduced tissue thickness. These dose inhomogeneities
may lead to increased late skin toxicity and increased cardiac and lung morbidity. IMRT has the potential to improve target
coverage and reduce inhomogeneities observed within the breast (and regional lymph nodes) and enables dose reduction to
normal structures with the potential to reduce treatment toxicity improving cosmesis.
Objectives. We present the initial experience of the ﬁrst breast cancer patients treated with IMRT in our centers in Málaga and
Granada.
Material and methods. 16 patients with breast cancer were referred to receive radiotherapy to our clinics. After individualized
evaluation in a clinical meeting, the patients were proposed to undergo IMRT treatment.
Results. Patient selection criteria: Left breast: 9, unfavourable chest wall: 4, patient decision: 2, irregular breast: 1 patient. Stage:
Early breast cancer: 10 patients, advanced breast cancer: 6 patients. Positive axillary nodes: 6 patients (all of them received
radiotherapy at supraclavicular area). Median prescribed dose to the whole breast was 42.56Gy, with fractionation of 2.66Gy. 12
patients received additional boost to the tumor bed, in 7 patients it was an integrated boost (median dose administered was
